Dr. Paola Scapoli
Providing Personalized Medicine with Nuclear Molecular Imaging in Cancer Patients - PET/CT in early evaluation of cancer treatment response and targeting resistance to molecular therapies.
Early differentiation between responders and non responders is a very important issue for the management of cancer patients. Wide evidence exists that FDG-PET can predict outcomes for many tumor types very soon after conventional systemic chemotherapy is started. In particular compared with cytotoxic chemotherapy, many novel targeted therapies result in disease stabilization rather than tumor shrinkage. The activity of these novel agents might, therefore, be better reflected by changes in molecular features of the tumor rather than reduction in size or volume. Recent prospective studies show that a change in tumor glucose activity (measured with FDG PET standard uptake value-SUV) is a significantly more accurate parameter than a change in size in assessing histopathological response to neoadjuvant therapy in patient with GIST and high grade soft tissue sarcoma.
The PET imaging facility has been qualified by CoreLab Partners, Inc. for the submission of Nuclear Medicine and PET images of the patients who are enrolled in the CAUY922A2109 study. The aim of this study is to evaluate the efficacy of AUY922 in combination with Trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer that has progressed after or during at least one Trastuzumab-containing regimen.
Conclusions and perspectives:
Research goals will be to assess the value of metabolic imaging with PET in predicting response to therapy, targeting resistance to molecular therapies, improving personalized therapy and prognosis.